Strong Revenue Growth
Cryoport reported a 14% increase in total revenue from operations for the second quarter, with a 21% year-over-year increase in service revenue and a 33% increase in revenue from commercial cell and gene therapies.
Successful Strategic Partnership with DHL
Cryoport launched a strategic partnership agreement with DHL Group, including a $200 million cash infusion from the sale of CRYOPDP to DHL, enhancing global bio logistics capabilities.
Increased Clinical Trial Support
Cryoport supported a record 728 clinical trials, approximately 70% of the industry cell and gene therapy trials, with the expectation of up to 20 application filings and one new therapy approval for the remainder of 2025.
Product Innovation
Launch of next-generation MVE SC 4/2 and SC 4/3 vapor shippers and MVE's high-efficiency 800-seat cryogenic storage system, supporting improved safety and reliability in transporting sensitive biological materials.
Improved Financial Metrics
Significant increase in gross margin and a meaningful lift in adjusted EBITDA due to profitability initiatives, with a reported 47% total gross margin.